VICTORIE (VTE IN CANCER - TREATMENT, OUTCOMES AND RESOURCE USE IN EUROPE)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Recurrence of Thromboembolism
研究概览
简要总结
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A VTE diagnosis
- •Active cancer or history of cancer
- •Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
- •Age ≥ 18 years at the date of index VTE (Venous thromboembolic)
排除标准
- •Prior VTE diagnosis
- •Diagnosis of prior atrial fibrillation
- •Inferior Vena Cava (IVC) filter
- •Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
- •Pregnancy
- •More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
- •Patients with less than one day of follow up
研究组 & 干预措施
VTE and history of cancer
VTE and history of cancer
干预措施: LMWH (Drug)
VTE and active cancer
VTE and active cancer
干预措施: VKA (Drug)
VTE and history of cancer
VTE and history of cancer
干预措施: VKA (Drug)
VTE and active cancer
VTE and active cancer
干预措施: LMWH (Drug)
VTE and history of cancer
VTE and history of cancer
干预措施: Apixaban (Drug)
VTE and history of cancer
VTE and history of cancer
干预措施: Rivaroxaban (Drug)
VTE and history of cancer
VTE and history of cancer
干预措施: Edoxaban (Drug)
VTE and history of cancer
VTE and history of cancer
干预措施: Dabigatran (Drug)
VTE and active cancer
VTE and active cancer
干预措施: Apixaban (Drug)
VTE and active cancer
VTE and active cancer
干预措施: Rivaroxaban (Drug)
VTE and active cancer
VTE and active cancer
干预措施: Edoxaban (Drug)
VTE and active cancer
VTE and active cancer
干预措施: Dabigatran (Drug)
结局指标
主要结局
Recurrence of Thromboembolism
时间窗: 6 Months after treatment began as early as 1/1/2013
The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first. As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.
次要结局
未报告次要终点